---
aliases:
- (Yee et al., 2005)
author: Yee, Su-Bog and Yeo, Won Jae and Park, Bong Soo and Kim, Ji Young and Baek,
  Soo Jin and Kim, Yoon Cheong and Seo, Su Young and Lee, Sang Hwa and Kim, Jae Hong
  and Suh, Hongsuk and Kim, Nam Deuk and Lim, Young Jin and Yoo, Young Hyun
citekey: yee2005SyntheticChenodeoxycholicAcid
date_added: '2025-03-23'
doi: ''
journal: International Journal of Oncology
title: Synthetic Chenodeoxycholic Acid Derivatives Inhibit Glioblastoma Multiform
  Tumor Growth in Vitro and in Vivo
year: '2005'

---
# Synthetic Chenodeoxycholic Acid Derivatives Inhibit Glioblastoma Multiform Tumor Growth in Vitro and in Vivo
- [PDF Link](zotero://open-pdf/library/items/IP2NPMLY)

Citation: [@yee2005SyntheticChenodeoxycholicAcid]

***
# TL;DR (Summary)
- HS-1199 and HS-1200 significantly reduced viability of four glioblastoma cell lines by 50 µM treatment (P<0.01).
- HS-1200 treatment in NOD/SCID mice reduced tumor size from the 69th day post-challenge (P<0.05) and extended survival to 91.64±8.80 days (P<0.01).
- HS-1200 decreased proteasome activity by approximately 50% in U87MG cells compared to control (P<0.01).
- First in vivo demonstration of the antitumor effect of synthetic chenodeoxycholic acid (CDCA) derivative HS-1200 on glioblastoma.
- Utilization of novel synthetic CDCA derivatives, HS-1199 and HS-1200, showing stronger apoptosis-inducing effects than natural CDCA.
- Authors suggest synthetic CDCA derivatives could be potential chemotherapeutic agents for glioblastoma.
- Future research should focus on identifying the exact molecular mechanisms and targets of synthetic CDCA derivatives in cancer cell apoptosis.
- Synthetic CDCA derivatives induce apoptosis via mitochondrial pathways, involving cytochrome c release and AIF translocation.
- The study highlights the role of proteasome inhibition in the apoptosis induced by synthetic CDCA derivatives.

# 中文摘要 (TL;DR)
- HS-1199和HS-1200在50微摩爾濃度下顯著降低了四種膠質母細胞瘤細胞系的存活率（P<0.01）。
- 在NOD/SCID小鼠中，HS-1200治療從挑戰後第69天開始顯著減少腫瘤大小（P<0.05），並延長存活時間至91.64±8.80天（P<0.01）。
- HS-1200在U87MG細胞中將蛋白酶體活性降低了約50%，與對照組相比（P<0.01）。
- 首次在體內展示合成鹼性膽酸（CDCA）衍生物HS-1200對膠質母細胞瘤的抗腫瘤效果。
- 使用新型合成CDCA衍生物HS-1199和HS-1200，顯示出比天然CDCA更強的誘導凋亡效果。
- 作者建議合成CDCA衍生物可能成為膠質母細胞瘤的潛在化療藥物。
- 未來研究應專注於確定合成CDCA衍生物在癌細胞凋亡中的確切分子機制和目標。
- 合成CDCA衍生物通過線粒體途徑誘導凋亡，涉及細胞色素c釋放和AIF轉位。
- 該研究強調了合成CDCA衍生物誘導凋亡中蛋白酶體抑制的作用。
